SCHEMBL26609583

SCHEMBL26609583

N#Cc1ccccc1C(=O)N1CCC(c2cc(F)cc3c2CN(C2CCC(=O)NC2=O)C3=O)CC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ IKZF2 Q9UKS7 4/20 0.49
▸ HSD11B1 P28845 1/20 0.44
▸ CRBN Q96SW2 13/20 0.44
▸ IKZF3 Q9UKT9 4/20 0.43
▸ IKZF1 Q13422 3/20 0.43
▸ CSNK1A1 P48729 2/20 0.43
▸ DDB1 Q16531 4/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ SLC9A1 P19634 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ BRD4 O60885 1/20 0.42
▸ TNF P01375 1/20 0.42
▸ IL1B P01584 1/20 0.42
▸ MAP1LC3B Q9GZQ8 1/20 0.40
▸ ADRA1D P25100 1/20 0.39
▸ ADRA1A P35348 1/20 0.39
▸ ADRA1B P35368 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26609418 0.90 IKZF2 (0.52) IKZF2CRBNIKZF3IKZF1CSNK1A1
SCHEMBL26610171 0.89 IKZF2 (0.51) IKZF2HSD11B1CRBNIKZF3IKZF1
SCHEMBL26609708 0.88 CRBN (0.51) IKZF2HSD11B1CRBNIKZF3IKZF1
SCHEMBL26609408 0.87 IKZF2 (0.48) IKZF2CRBNIKZF3IKZF1CSNK1A1
SCHEMBL26609730 0.87 IKZF2 (0.53) IKZF2CRBNIKZF3IKZF1CSNK1A1
SCHEMBL26609441 0.87 IKZF2 (0.49) IKZF2CRBNIKZF3IKZF1CSNK1A1
SCHEMBL26609895 0.87 IKZF2 (0.56) IKZF2HSD11B1CRBNIKZF3IKZF1
SCHEMBL26609072 0.86 CRBN (0.47) IKZF2CRBNIKZF3IKZF1CSNK1A1
SCHEMBL26610365 0.85 IKZF2 (0.49) IKZF2CRBNIKZF3IKZF1CSNK1A1
SCHEMBL26608655 0.84 CRBN (0.56) IKZF2CRBNIKZF3IKZF1CSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-10-26 — — US claimed
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-10-26 — — US disclosed
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-10-26 — — US disclosed
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-10-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS CSNK1A1, CSNK1D, CSNK1G1 IKZF2 2228/4885HSD11B1 494/4885CRBN 2723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback